CIPLA's weekly performance was disappointing, with a return of -0.64%, indicating a decline in stock value. The stock's volatility was moderate at 16.1%, suggesting a relatively stable price movement. Compared to its peers, CIPLA underperformed SUNPHARMA and GRASIM, but outperformed DIVISLAB. The stock's Sharpe ratio of -0.21 and max drawdown of -1.42% indicate a relatively risky investment this week.

[Volatility: 16.1%]